PV Bulletin

Use of AI in GXP Inspection Responses

MHRA guidance emphasizes accuracy in AI-generated responses to inspections, impacting workflows.

Primary source: Medicines and Healthcare products Regulatory Agency (MHRA)

PV Impact Brief

Urgency: HighConfidence: high

What changed

Organizations must implement quality checks for AI-generated content used in responses to ensure factual accuracy and compliance with MHRA standards.

Why it matters

Inaccurate information in submissions may lead to delays, increased scrutiny, or rejection of responses, placing a strain on resources and regulatory compliance.

Action needed

Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.

Relevant for
Regulatory Intelligence LeadPV Quality Lead
Processes impacted
Inspection ReadinessCAPA
Owner

Regulatory Intelligence Lead

Review cadence

Review in the next regulatory intelligence cycle.

Policy change details

Document type
Guidance / Notice
Policy status
effective
Publication date
2026-06-29
Policy change
MHRA guidance published on the Inspectorate Blog regarding the use of Artificial Intelligence (AI) when drafting responses to GxP inspection findings.

Key changes

Establishes expectations for the use of AI in regulatory communications. Emphasizes that MAHs and sponsors are fully responsible for the accuracy of AI-generated content and warns against inaccuracies or 'hallucinations' in inspection responses.

Affected workflows

Inspection ReadinessCAPA

Responsible groups

Quality AssurancePV QualityCompliance Team

PV impact

Impacts inspection readiness and CAPA workflows. Organizations using AI for drafting responses must implement quality checks to ensure citations and factual claims are accurate to avoid regulatory non-compliance.

View regulator source

Source document details

Exact policy details

Responsibility for Accuracy
Organizations must ensure the accuracy of their submissions to the MHRA.
Applies to: All organizations submitting responses to MHRA.
Organisations have always been responsible for the accuracy of their responses to the MHRA and persons responsible for them have always been expected to verify factual claims. · p. 1 · High · Source
Expectations for Submission Accuracy
All submissions/responses must be factually accurate and verifiable.
Applies to: Applicable to all submissions to MHRA Compliance Teams.
All submissions/responses must be: factually accurate and verifiable. · p. 1 · High · Source
Impact of Inaccurate Information
Inaccurate submissions may lead to rejection or request for resubmission.
Applies to: Responses to MHRA inspections.
if the information supplied in response to an inspection is inaccurate, incomplete or overly verbose then we may reject the response or return it for another attempt. · p. 1 · High · Source
Disclosure of AI Use
Organizations can voluntarily disclose AI use in submissions.
Applies to: Applicable to organizations using AI in responses.
we are offering organisations the option to disclose AI use in responses/submissions to the compliance teams. · p. 1 · High · Source

Workflow rule impacts

Inspection ReadinessCompliance Teams

Increased scrutiny of submissions and potential resource strain if AI tools are misused.

Expectations for accuracy and oversight are higher due to AI tool usage.

As AI becomes more sophisticated, this framework remains relevant because it focuses on accountability and process. · p. 1 · High · Source

Evidence and confidence

Confidence: highSource updated: Jun 29, 2026

Full briefing

Practical implication

Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.

The MHRA has released guidance on the use of AI in drafting responses to GxP inspection findings. It underscores that organizations are fully accountable for the accuracy of AI-generated content, warning against inaccuracies that could lead to regulatory non-compliance. The guidance includes higher expectations for submission accuracy due to the use of AI, impacting inspection readiness and corrective action preventive action (CAPA) processes.

What changed: Organizations must implement quality checks for AI-generated content used in responses to ensure factual accuracy and compliance with MHRA standards.

Why it matters: Inaccurate information in submissions may lead to delays, increased scrutiny, or rejection of responses, placing a strain on resources and regulatory compliance.

Practical implication: Implement mandatory quality checks and oversight for all AI-generated inspection responses to meet MHRA expectations for accuracy.

View original source

Published from the Firecrawl policy change extraction pipeline.

Related updates for your role

publicTherapeutics Goods Administration · Australia · Updated Jul 20, 2026

Updates on ISO 14155 and N=1 Therapeutics Discussed by TGA

Urgency: High

Investigators need to modify trial protocols and safety reporting mechanisms in line with the latest ISO 14155 updates to ensure compliance for upcoming high-risk clinical trials.

Inspection ReadinessICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Notice
Read impact briefarrow_forward
publicMedicines and Healthcare products Regulatory Agency (MHRA) · United Kingdom · Updated May 23, 2026

MHRA confirms UK clinical trial safety reporting guidance is effective

Urgency: High

Safety lead to: (1) perform a UK-clinical-trial safety reporting gap assessment against MHRA’s effective guidance sections (MedDRA coding; AE/SAE; RSI governance; SUSARs; annual safety reporting; USMs; serious breaches; temporary suspension), (2) update controlled SOPs/WIs and training records to reflect “effective” status as of 28 Apr 2026, and (3) document deviations/gaps and open CAPA where needed for ongoing UK trials and new submissions.

ICSRCountry ComplianceRegulatory Intelligence Lead
SOP Impact4 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, QPPV
verifiedRegulatory action: Guidance
Read impact briefarrow_forward
publicEuropean Medicines Agency (EMA) · European Union · Updated Jul 20, 2026

CHMP Draft Agenda for Public Consultation on Thalassaemia and Sickle Cell Disease Guidelines

Urgency: High

Sponsors and MAHs must review and align safety data collection and reporting protocols with the newly adopted guidelines while preparing for implementation of PRAC recommendations stemming from this meeting.

Signal ManagementICSRRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, Signal Management Lead
verifiedRegulatory action: Agenda
Read impact briefarrow_forward
publicSwissmedic · Switzerland · Updated Jul 17, 2026

Checklist for the Inspection of Medical Device Vigilance in Hospitals

Urgency: High

Healthcare facilities must utilize the new checklist during inspections to conduct gap analyses and ensure compliance with reporting requirements associated with their vigilance systems.

Inspection ReadinessRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead, PV Quality Lead
verifiedRegulatory action: Checklist
Read impact briefarrow_forward